Alx Oncology Holdings Inc (NASDAQ: ALXO)

ALX Oncology Holdings Inc., also known as ALXO, operates in the immuno-oncology industry, focusing on the development of therapies that block the CD47 immune checkpoint and bridge the innate and adaptive immune system. The company's main business activities revolve around its lead product candidate, evorpacept, which is a next-generation CD47 blocking therapeutic designed to have a high affinity for CD47 and avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. ALXO's strategic goal is to expand the therapeutic potential of CD47 blockade by combining evorpacept with anti-cancer antibodies and antibody-drug conjugates (ADCs), as well as exploring the potential of combining evorpacept with PD-1/PD-L1 immune checkpoint inhibitors to enhance the anti-tumor activity of these therapies.

ALXO's pipeline is focused on targeting CD47 across various oncology indications, including solid tumors and hematologic malignancies. The company's clinical programs include ASPEN-06, a randomized Phase 2/3 trial of evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel for the treatment of second- and third-line advanced HER2-overexpressing gastric/GEJ cancer; ASPEN-07, a Phase 1 trial of evorpacept in combination with an ADC, enfortumab vedotin-ejfv, for the second-line treatment of locally advanced or metastatic urothelial cancer; ASPEN-03, a randomized Phase 2 trial of evorpacept in combination with pembrolizumab for the treatment of first-line advanced PD-L1-positive head and neck squamous cell carcinoma; and ASPEN-04, a randomized Phase 2 trial of evorpacept in combination with pembrolizumab, platinum, and fluorouracil for the treatment of first-line advanced head and neck squamous cell carcinoma. ALXO's preclinical program is focused on developing ALTA-002, a SIRPα TRAAC that may offer additional ways to engage the innate and adaptive immune response to cancer.

The company's revenue generation is dependent on the success of its product candidates in clinical trials and their subsequent approval and commercialization. ALXO's primary products include evorpacept, a fusion protein designed to provide a high CD47 blocking potency while potentially eliminating any associated toxicities. Preclinical studies of evorpacept support a target product profile of favorable tolerability, the ability to be dosed at high levels, and increased anti-tumor activity compared to other CD47 blocking agents. Clinical data from evorpacept's Phase 1 trials have consistently demonstrated a favorable tolerability profile, with low occurrences of cytopenias and other toxicities.

In the immuno-oncology industry, ALXO competes with various companies, including those focused on developing therapies that target CD47. However, ALXO's competitive advantage lies in its approach to blocking CD47, which is designed to overcome the limitations of current approaches, including limited dosing and therapeutic window, limited ability to combine with other anti-cancer agents, and limited efficacy in solid tumors.

ALXO's scientific background is based on the understanding that cancer immunotherapies targeting adaptive immune system checkpoints, such as PD-1/PD-L1, have transformed the standard of care in oncology across multiple cancer types. However, emerging evidence demonstrates that the innate immune system plays a crucial role in the first line of defense to eliminate transformed malignant cells and the subsequent activation of the adaptive immune system. ALXO's CD47 scientific background is based on the understanding that cancer cells evade phagocytosis by up-regulating CD47, a transmembrane protein that mainly functions as an anti-phagocytic "don't eat me" signal for healthy cells. By overexpressing CD47, cancer cells are able to avoid phagocytosis by macrophages and thereby evade subsequent detection by the adaptive immune system.

ALXO's pipeline is designed to maximize phagocytosis of cancer cells and activation of the adaptive immune system by targeting CD47 and combining it with anti-cancer antibodies and ADCs. The innate immune system's role in eliminating malignant cells and activating the adaptive immune system is crucial, and ALXO's approach aims to harness this potential to improve cancer treatment options.